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as the hypomethylating agents, azacitidine and decitabine, which have been administered adjunctively to reverse broadspectrum chemoresistance, are associated with prolonged dose-limiting myelosuppression and gastrointestinal toxicity even at lower doses. 12 In contrast, the nonmyelosuppressive properties of RRx-001, 6 which generally lead to the recovery of normal blood counts during treatment, are the basis for a sequential schedule of RRx-001 administered until radiologic progression followed by introduction or reintroduction of the firstline chemotherapy (Fig. 1) .
In the context of treatment of small cell lung cancer (SCLC), non-SCLC (NSCLC), or high-grade neuroendocrine tumor (HGNET) patients, the first-line therapy is typically a platinum doublet with platinum (cisplatin or carboplatin) matched with etoposide (EP), nab-paclitaxel, or paclitaxel. Food and Drug Administration-approved salvage therapies that would be available to this patient population include docetaxel for NSCLC, topotecan for SCLC, and none for HGNET.
In addition, serial tumor biopsies have demonstrated that RRx-001 initiates an immunologically driven inflammatory and edematous response 9, 13 and not uncommonly misinterpreted as tumor progression on 6-or 8-week scans, 14 which is potentially a further justification for sequential dosing of RRx-001 followed by chemotherapy, since it may take up to 12 weeks to resolve the inflammation and edema and to shrink or stabilize the tumor.
In the four-arm sequentially designed Phase II clinical trial called QUADRUPLE THREAT (formerly TRIPLE THREAT; NCT02489903), patients with SCLC, NSCLC, HGNET, and resistant/refractory ovarian tumors (hence, the QUADRUPLE in the title) are reintroduced to the firstline platinum doublets following disease progression on RRx-001 (Fig. 2) .
Of the tumors studied in this trial, recurrent resistant SCLC (rSCLC) arguably has the most aggressive, drugresistant phenotype with a response rate (RR) of less than 10% 15, 16 and an overall survival of less than six months. 17 Therefore, resensitization to platinum doublets in this patient population is a virtual impossibility. Herein, we present an 82-year-old rSCLC patient who achieved a partial response on platinum doublets after 12 weeks of priming with RRx-001 in the QUADRUPLE THREAT clinical trial. After over three decades of no new treatments in SCLC, 18 any favorable response is a potentially publishable case, especially in the recurrent-resistant setting, 19 where Rather than this expected downward spiral of functional decline, the patient has maintained a good performance status over the course of his participation in the QUADRUPLE THREAT clinical trial.
case
The patient is a 82-year-old white male diagnosed in June 2015 with extrapulmonary SCLC, manifesting HPV-positive small cell carcinoma at the left base of the tongue metastatic to the liver (clinical stage T3, N0, and M1). The patient initially received six cycles of carboplatin-EP on July 7, 2015, but progressed one month after its completion, meeting the definition of resistant disease. The platinum doublets were followed on December 12th, 2015, by palliative radiotherapy (XRT) to the neck. On January 14, 2016, having histologically or cytologically confirmed SCLC with a metastatic liver lesion as the primary lesion, the patient enrolled on NCT02489903 and began weekly intravenous treatment with 4 mg RRx-001 coinfused with autologous blood. At the time of enrollment, his performance status was ECOG 1 with fatigue and decreased appetite as his chief complaints. Within one week of starting RRx-001, the patient reported normalization of energy and appetite, resulting in an improvement of general demeanor and level of alertness. No systemic side effects related to treatment were observed. The first six-week restaging computerized tomography (CT) scan demonstrated stable disease, which resulted in the continuation of therapy. However, the 12-week CT scan demonstrated progressive disease per RECIST v.1.1 criteria. At this point, per protocol, RRx-001 was discontinued, and carboplatin-EP was reintroduced with the plan to repeat CT scans after every two cycles (six weeks). To date, the EP regimen has been very well tolerated with no myelosuppression. The CT scan at week 6 was classified as a partial response with a 32% reduction in target liver lesions (Fig. 3) . The management plan for this patient is to continue treatment with carboplatin-EP for up to six cycles, with repeat CT every six weeks until disease progression or intolerable toxicity.
discussion
Progress in SCLC, a relentlessly aggressive, rapidly metastasizing, and highly fatal neoplasm, 23 has remained lamentably stagnant for decades, and an active, nontoxic chemotherapeutic regimen, especially in the resistant/recurrent setting, is notably lacking for this disease. The rarity of desirable responses in rSCLC coupled with a lack of effective, nontoxic therapies is the motivation for this case report, which describes clinical benefit in the form of a .30% reduction in tumor sizes after only two cycles (six weeks) of reintroduced platinum therapy following a priming period with RRx-001 and maintenance/improvement of ECOG performance status. While it is manifestly too early to generalize and extrapolate the efficacy of RRx-001 in SCLC from this patient, partial responses have also been reported for two other rSCLC patients in the QUADRUPLE THREAT trial, 9 which suggests a developing trend.
Two of the key RRx-001 antiresistance mechanisms are epigenetic inhibition 24 and immune stimulation 9, 13 ; however, a hallmark of any successful sensitizer is target promiscuity, and RRx-001, which is no exception, 25 also possesses prooxidant, apoptotic, 24, 26 antiangiogenic, 27 and P-gp inhibitory properties. Recently published case reports of partial responses in NSCLC 13, 28 in the QUADRUPLE THREAT trial raise the possibility that RRx-001 may broadly alter the multidrug resistance phenotype, sensitizing or resensitizing heavily pretreated patients with platinum-based resistance in other nonthoracic tumor types where doublet regimens are approved or considered the mainstay of care, such as gastroesophageal, transitional cell and bladder cancer, cervical, testicular, and head and neck cancers. Additional studies are needed in support of this hypothesis and early observations.
conclusion
This case report describes a new rechallenge strategy with RRx-001 in the management of a patient with recurrent SCLC/rSCLC, a tumor type known for its poor clinical response to chemotherapy. Additional cases are needed to determine whether RRx-001 is beneficial in SCLC.
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